Related references
Note: Only part of the references are listed.Nifedipine Induces Peroxisome Proliferator-Activated Receptor-γ Activation in Macrophages and Suppresses the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice
Norio Ishii et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Mineralocorticoid Receptors, Salt-Sensitive Hypertension, and Metabolic Syndrome
Toshiro Fujita
HYPERTENSION (2010)
Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
Michel Burnier et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Cardioprotective effect of benidipine on cardiac performance and remodeling in failing rat hearts
Tomoyuki Ohno et al.
AMERICAN JOURNAL OF HYPERTENSION (2008)
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models
Yomiko Tomono et al.
AMERICAN JOURNAL OF HYPERTENSION (2008)
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity
Jessica D. Dietz et al.
HYPERTENSION (2008)
Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation
Gabriella Passacquale et al.
JOURNAL OF HYPERTENSION (2008)
TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation
Masaru Iwai et al.
AMERICAN JOURNAL OF HYPERTENSION (2007)
The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients
Roberto Negro et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2006)
Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan
Masarsu Iwai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage
Masaru Iwai et al.
JOURNAL OF HYPERTENSION (2006)
Regression of Atherosclerosis by Amlodipine via Anti-Inflammatory and Anti-Oxidative Stress Actions
Toyofumi Yoshii et al.
HYPERTENSION RESEARCH (2006)
Nifedipine inhibited angiotensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor kappa B kinase and nuclear factor kappa B-inducing kinase
L Wu et al.
JOURNAL OF HYPERTENSION (2006)
Peroxisome proliferator-activated receptor (PPAR)α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue -: Comparison of activation of PPARα, PPAR-γ, and their combination
A Tsuchida et al.
DIABETES (2005)
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes - A meta-analysis of randomized clinical trials
H Abuissa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress
M Tsuda et al.
HYPERTENSION (2005)
Nuclear receptors as targets for drug development:: Molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor γ, CREB-binding protein, and adiponectin
A Tsuchida et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2005)
Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance
K Shinozaki et al.
HYPERTENSION (2004)
Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan
T Jinno et al.
HYPERTENSION (2004)
Insulin resistance and hypertension - The Insulin Resistance Atherosclerosis Study
MF Saad et al.
HYPERTENSION (2004)
Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation
F Massiéra et al.
FASEB JOURNAL (2001)
Share Paper
